Eupraxia Pharmaceuticals Files 6-K Report
Ticker: EPRX · Form: 6-K · Filed: Sep 24, 2025 · CIK: 1581178
Sentiment: neutral
Topics: foreign-private-issuer, regulatory-filing, sec-filing
TL;DR
Eupraxia Pharma (EPRX) filed a 6-K, standard foreign issuer report.
AI Summary
Eupraxia Pharmaceuticals Inc. filed a Form 6-K on September 24, 2025, reporting as a foreign private issuer. The company is incorporated in Canada and its fiscal year ends on December 31. This filing is made under the Securities Exchange Act of 1934.
Why It Matters
This filing provides routine updates for investors and regulators regarding Eupraxia Pharmaceuticals Inc.'s status as a foreign private issuer.
Risk Assessment
Risk Level: low — This is a routine filing for a foreign private issuer and does not contain significant new financial or operational information.
Key Players & Entities
- EUPRAXIA PHARMACEUTICALS INC. (company) — Registrant
- 001-41923 (company) — SEC File Number
- 201-2067 Cadboro Bay Road Victoria, British Columbia, Canada V8R 5G4 (company) — Principal Executive Office Address
- 250-590-3968 (company) — Telephone Number
FAQ
What is the purpose of a Form 6-K filing?
A Form 6-K is a report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934, used to provide information that the registrant has made or is required to make public pursuant to the laws of its home country.
When was this Form 6-K filed?
This Form 6-K was filed on September 24, 2025.
What is Eupraxia Pharmaceuticals Inc.'s principal executive office address?
Eupraxia Pharmaceuticals Inc.'s principal executive office is located at 201-2067 Cadboro Bay Road, Victoria, British Columbia, Canada V8R 5G4.
Does Eupraxia Pharmaceuticals Inc. file an annual report under Form 20-F or Form 40-F?
Eupraxia Pharmaceuticals Inc. indicates it files an annual report under Form 40-F.
What is the SIC code for Eupraxia Pharmaceuticals Inc.?
The Standard Industrial Classification (SIC) code for Eupraxia Pharmaceuticals Inc. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 172 words · 1 min read · ~1 pages · Grade level 13.1 · Accepted 2025-09-24 11:12:31
Filing Documents
- f6k_092425.htm (6-K) — 6KB
- exh_991.htm (EX-99.1) — 10KB
- 0001171843-25-006052.txt ( ) — 17KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. EUPRAXIA PHARMACEUTICALS INC. Date: September 24, 2025 By: /s/ Alex Rothwell Name: Alex Rothwell Title: Chief Financial Officer